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Abstract
Background: A large proportion of patients with T2DM in China do not meet accepted HbA1c targets despite the
availability of guidelines that describe a treatment pathway for achieving glycemic control. The aim of this study is
to identify the fasting plasma glucose (FPG) target that will provide the highest control rate of HbA1c <7 % in
Chinese patients with T2DM treated with an insulin glargine-based regimen as an adjunct to an established OAD
regimen. This information will support improvements in diabetes care management in China.
Methods: Approximately 934 men and women aged ≥18 to ≤65 years with poorly controlled T2DM will be
enrolled and randomized to one of three FPG target groups; ≤5.6 mmol/L, ≤6.1 mmol/L, or ≤7.0 mmol/L. They will
be initiated on daily insulin glargine (Lantus®) in addition to their usual OAD regimen for 24 weeks. Patients will
self-monitor fasting blood glucose (SM-FBG), and the study physician will titrate the basal insulin dose according to
the SM-FBG results. In addition, HbA1c and safety will be recorded. We plan to statistically derive the optimal FPG
target for an HbA1c of <7 %.
Discussion: In China, treatment strategies that would achieve an optimum balance between glycemic control (as
per HbA1c) and hypoglycemia are imperative to ensure improvements in the management of T2DM. Furthermore,
elucidating the contribution of FPG to HbA1c in Chinese patients with T2DM and identifying a predictable
relationship between FPG and HbA1c would be a valuable tool for patient self-management of diabetes.
Trial registration: NCT02545842. Registered on 8 September 2015.
Keywords: Type 2 diabetes mellitus, Oral antidiabetic drugs, Fasting plasma glucose, Self-monitor fasting blood
glucose, glycated hemoglobin
Background
Globally, type 2 diabetes mellitus (T2DM) has become a
considerable economic burden owing to the impact of
the disease in terms of costs to society, health systems,
individuals, and employers, and in terms of a reduction
in the productive workforce and productivity in general
[1, 2]. In China, the impact of T2DM is particularly
disconcerting: the Chinese T2DM population is nearing
100 million individuals—about a quarter of the global
T2DM population—and is projected to reach 142.7 mil-
lion by 2035 [3–5]. Moreover, recent data suggest that,
in general, patients with T2DM in China have poor gly-
cemic control; a large observational study conducted at
209 hospitals across China found that patients had a
mean hemoglobin A1c (HbA1c) level of 9.6 ± 2.0 % be-
fore initiation of basal insulin [6], and it has been re-
ported that only 35.9 % of Chinese T2DM patients who
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are treated exclusively with oral antidiabetic drugs
(OADs) achieve HbA1c levels of <7 % [7].
HbA1c has become the standard for assessing and
monitoring glycemic control in patients with diabetes,
and HbA1c has been the independent variable against
which rates of complications in all major trials have been
assessed [8–11]. Several large epidemiological studies
have implicated the association of high HbA1c values
(i.e., values higher than 7 %) and the development of
complications of diabetes, especially atherosclerosis and
other microvascular and macrovascular complications
[12–14]. Correspondingly, there is a strong association
between a decrease in HbA1c and a reduction in
T2DM-related complications. For instance, the UK Pro-
spective Diabetes Study (UKPDS) study found a 35 % re-
duction in the risk of microvascular complications for
each 1 % decrement in HbA1c [15]. Furthermore, there
is thought to be a relationship between HbA1c and fast-
ing plasma glucose (FPG). To date, several studies have
explored the exact nature of this relationship, i.e., the
FPG target that would correspond with HbA1c values
that define glycemic control. The ORIGIN study demon-
strated a graded relationship between FPG ≥5.6 mmol/L
and HbA1c levels [16], and a US-based study reported
that an FPG target of 5.6–6.1 mmol/L provided an
optimum balance between HbA1c and hypoglycemic
events [17].
T2DM patients who do not meet HbA1c targets with
lifestyle modifications and OADs are commonly initiated
on basal insulin as an adjunct to OADs. The safety and
efficacy of basal insulin as an adjunct to OADs have
been confirmed by several global studies (reviewed by
Cahn et al. [18]), and this is a conventional treatment
approach to glycemic control and an established prac-
tice, especially in Western countries [19]. Nonetheless,
there are some limitations to this therapeutic approach;
for instance, the TITRATE study showed that although
the majority of T2DM patients who were initiated on
once-daily basal insulin following inadequate glycemic
control with OADs, achieved an HbA1c level of <7 %,
they did not achieve FPG targets of 3.9–5.0 mmol/L or
4.4–6.1 mmol/L [20]. Furthermore, there are profound
differences in T2DM pathophysiology in Asians and
Westerns [21], and the FPG targets for basal insulin
therapy in Caucasian patients may well not be appro-
priate for Asians. In Asians, T2DM develops at a
lower mean body mass index than in individuals of
European descent, and Asian T2DM is characterized
by early β cell dysfunction, which may necessitate
early initiation of insulin therapy. In general, Asian
patients with T2DM have a higher degree of insulin
resistance, higher postprandial glucose excursions, and
higher incidence of hypoglycemia than Westerners
with T2DM [22, 23].
Currently, the relationship between HbA1c and FPG
in Chinese patients with T2DM is poorly understood.
The Chinese Diabetic Society’s treatment guidelines rec-
ommend the initiation of insulin (basal or premix insu-
lin) if lifestyle changes and an OAD regimen fail to
achieve glycemic control [24]. However, only a limited
number of studies have investigated the efficacy of insu-
lin glargine-based treatment in Chinese patients with
T2DM to date. Moreover, these studies were unable to
identify a clear and consistent FPG target that would
suggest appropriate glycemic control [25, 26]. Data are
needed to elucidate the contribution of FPG to HbA1c
in Chinese patients with T2DM. Identifying effective
FPG targets would enable Chinese physicians to opti-
mally treat their patients with reduced concerns about
hypoglycemia. Also, finding a predictable relationship
between FPG and HbA1c could be a valuable tool in pa-
tient self-management of diabetes, as FPG can be self-
monitored.
The primary objective of the present study is to iden-
tify the FPG target that will provide the highest control
rate of HbA1c <7 % in Chinese patients with T2DM
treated with an insulin glargine (Lantus®)-based regimen
as an adjunct to an established regimen of OADs. To
this end, the study’s primary end point is HbA1c ≤7 %
after 24 weeks of treatment with insulin glargine in
addition to OADs ± sulfonylurea (SU).
Secondary end points include: the control rate of
HbA1c ≤6.5 % and HbA1c <7.0 % in patients who
achieve their assigned FPG target; the percentage of pa-
tients who achieve HbA1c <7 % without hypoglycemia
per FPG target group; reduction in HbA1c, FPG and
postprandial glucose (PPG) from baseline (week 1) to
week 24; and the mean insulin dose of each FPG group
at the end of the treatment period. Safety and quality of
life will also be assessed. For safety end points, frequency
and severity of adverse events, rate of hypoglycemia,
subgroup analysis of hypoglycemia occurrence by the
use of SU intra-group and inter-group, change of labora-
tory tests and vital signs, change in weight in each treat-
ment arm from beginning to the end of the study will be
assessed.
Our study will also conduct a cost-effectiveness ana-
lysis evaluating patient quality of life and medical costs
to better understand the impact of improved HbA1c
control on patients’ quality of life and financial burden.
Methods
This prospective, randomized, three-arm parallel-group,
open-label, treat-to-target study will be conducted at
multiple centers across China (clinical study number:
NCT02545842). The study will be executed in accord-
ance with the Declaration of Helsinki and in line with
the principles of Good Clinical Practice.
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Patients
The study plans to enroll 934 men and women ≥18 to
≤65 years of age with poorly controlled T2DM. Poorly
controlled T2DM is defined as an HbA1c of >7 % des-
pite stable treatment with one to three OADs for a
period of at least 3 months prior to study entry. Patients
with HbA1c ≤10.5 % will not be eligible for enrollment.
Study design
The study design is shown in Fig. 1. Briefly, patients will
be stratified according to the presence/absence of SU in
their usual treatment regimen and randomized in a 1:3:3
ratio to one of three FPG target groups: ≤5.6 mmol/L,
≤6.1 mmol/L, or ≤7.0 mmol/L.
Patients will be required to continue with their usual
OADs for the duration of the study. Changes to a pa-
tient’s usual treatment can be made at the investigators’
discretion based on safety reasons (i.e., hypoglycemia)
and in accordance with Chinese treatment guidelines
and local label indications. However, patients will not be
allowed to discontinue or initiate SU during the treat-
ment period.
All study patients will initiate insulin glargine at a dose
of 0.2 U/kg as an adjunct therapy to their usual treat-
ment regimen. Patients will be required to inject insulin
glargine using a prefilled disposable pen, which contains
a 3-mL cartridge of insulin glargine suspension for injec-
tion (Lantus® SoloSTAR®, Sanofi-Aventis Deutschland
GmbH, Frankfurt, Germany).
During the 24-week treatment period, patients will
self-monitor fasting blood glucose (SM-FBG) at least
three times per week for the first 8 weeks and twice per
week from week 8 onward after a fasting period of
8 hours using a provided glucose meter. See Fig. 2 for a
schedule of visits and assessments.
The study physician will review the SM-FBG values
once a week for the first 8 weeks and every 2 weeks there-
after. For these assessments, patients will be contacted by
telephone, and they will visit the clinic on alternate weeks.
Also, patients will be required to provide the study phys-
ician with three SM-FBG results from three consecutive
days before the assessment call or visit as well as the insu-
lin dose administered on the day prior to each visit.
The study physician will titrate the basal insulin
dose according to the SM-FBG results and the treat-
ment group to which a patient has been assigned.
Table 1 details the titration regimes.
To monitor the titration practice and to ensure that
appropriate titration algorithms are followed by study
physicians at the different study sites, a Study Titration
Fig. 1 Schematic flow diagram of the study design. FPG fasting plasma glucose, OAD oral antihyperglycemic drug
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Committee will periodically review the insulin doses that are
prescribed. The Committee will convene regularly
and, if necessary, will contact sites directly to address
or clarify issues in the titration scheme implementa-
tion (Fig. 3).
The HbA1c levels of all patients will be measured during
the screening visit (baseline), which will take place within
2 weeks before study entry, and then after 12 and 24 weeks
of treatment. A 2-h postbreakfast blood glucose profile will
be obtained on the day prior to the start of treatment (base-
line), at week 12 and 24.
Laboratory tests will be performed on the day of screen-
ing, at week 12 and 24. Laboratory data will consist of
blood analyses (biochemistry and blood count). Vital signs,
including blood pressure and heart rate, will be measured
on the day of screening, at baseline and week 24. Body
weight will be measured on the day of screening, at base-
line, at week 12 and 24. The same weighing scale will be
used through the study.
Statistical methods
As per the randomization schedule, 120 patients will be
assigned to the FPG ≤5.6 mmol/L group, and 360 pa-
tients will be assigned to the FPG ≤6.1 mmol/L and to
≤7.0 mmol/L groups, respectively. After accounting for a
dropout rate of approximately 10 %, the study has 85 %
power to detect between-group differences of 15 %
(45 % versus 30 %) at a two-sided significant level of
0.05. Also, the study has 80 % power to detect differ-
ences of 10 % (40 % versus 30 %) between the FPG
≤6.1 mmol/L and ≤7.0 mmol/L groups. Descriptive
analysis will be performed for interim analysis of
safety and efficacy.
Interim analysis
For the interim analysis, a descriptive efficacy and safety
analysis will be performed when 300 subjects complete
the study.
Fig. 2 Schedule of visits, treatment, and data collection
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Final analysis
The primary efficacy end point is the percentage of pa-
tients reaching HbA1c <7 %, and two hierarchical null
hypotheses (H1 and H2) are defined to identify the opti-
mal FPG target for an HbA1c of <7 %.
H1 presumes no difference between the FPG
<5.6 mmol/L and the FPG <7.0 mmol/L target groups,
and H2 presumes no difference between the FPG
<6.1 mmol/L and FPG <7.0 mmol/L target groups.
These hypotheses will be tested in sequence, if need be,
i.e., H2 will only be tested if H1 is rejected.
A subgroup analysis of control rate of HbA1c <7 % by
duration of diabetes, duration of OAD treatment, base-
line FPG, baseline HbA1c, and age will also be
conducted.
Changes from baseline HbA1c levels, FPG, and PPG
will be estimated as: change = value at postbaseline visit
– value at baseline visit.
Changes from baseline to each postbaseline visit will
be estimated using a mixed model [PROC MIXED in
SAS (SAS Institute, Cary, NC, USA) or similar], with the
results used to test whether there are any differences in
the change from baseline by treatment arm. The model
will use the end-of-study HbA1c, FPG, or PPG value as
the dependent variable, with treatment, stratum, and
study site as fixed effects, baseline HbA1c, FPG, or PPG
as a covariate, and patient/visit as a repeated measure
indicator. Treatment-emergent adverse events, including
episodes of hypoglycemia as identified from patient diar-
ies, will be summarized. The number of events, and the
number and percentage of patients experiencing
hypoglycemia, including symptomatic hypoglycemia,
confirmed hypoglycemia, severe hypoglycemia, and noc-
turnal hypoglycemia, will be compared between FPG tar-
get groups and between patients stratified according to
the use of SU (with or without SU).
Discussion
Effective diabetes care management requires practical
implementation of evidence-based treatment strategies
in routine-care settings. Although Chinese physicians
are familiar with Chinese Diabetes Society guideline rec-
ommendations for the management of T2DM, evidence
shows that many Chinese T2DM patients have poor gly-
cemic control [6, 27, 28]. A possible reason for this is
the overly cautious approach to insulin initiation and ti-
tration, which, in turn, is thought to be a result of phys-
ician anxiety about invoking events of hypoglycemia in
patients.
Although hypoglycemia can be the result of tight gly-
cemic control, the consequences of uncontrolled blood
glucose levels are debilitating and irreversible.
The current gold standard for monitoring glycemic
control in T2DM is HbA1c levels, with HbA1c ≤6.5 or
<7 % being considered the optimum. HbA1c levels are
tested in the laboratory and usually every 3 months, and
so this procedure is not available to patients as a self-
monitoring tool [9–11]. Several studies have tried to
identify a relationship between HbA1c and FPG, but
overall the results are inconclusive [16, 17].
Knowledge of the relationship between HbA1c and
FPG would allow for patient self-monitoring of glycemic
control because FPG would serve as a proxy for HbA1c.
Moreover, it would allow for treatment strategies that
achieve an optimum balance between glycemic control
(as per HbA1c) and hypoglycemia.
Fig. 3 Titration Committee detailed information
Table 1 Insulin dose adjustment for each study group
FPG (mmol/L) Insulin dose
All groups≤ 3.9 or nocturnal hypoglycemia - 2 U
Group 1: 3.9 < FPG≤ 5.6 No change
Group 2: 3.9 < FPG≤ 6.1
Group 3: 3.9 < FPG≤ 7.0
Group 1: FPG > 5.6 +2 U
Group 2: FPG > 6.1
Group 3: FPG > 7.0
FPG fasting plasma glucose
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The primary objective of BEYOND III is to identify the
FPG target that would provide the highest control rate for
HbA1c with low rates of hypoglycemia using insulin glar-
gine as an adjunct treatment to OADs in Chinese patients
with T2DM. These results would inform about the best
practice for diabetes care management in China. Further-
more, the study will assess the cost-effectiveness of the in-
sulin glargine treatment regimen so as to contribute to
current pharmacoeconomic data. A recent meta-analysis
reported that the economic impact of T2DM is consider-
able, but more data are needed from developing econ-
omies such as China and India where the healthcare cost
of T2DM is expected to soar because of the size of the
T2DM population in these countries [29].
For BEYOND III, three FPG targets were identified:
≤5.6 mmol/L, ≤6.1 mmol/L, and ≤7 mmol/L. The lower
targets are based on the recommendations from inter-
national and domestic guidelines, and previous study re-
sults [9, 10, 26], whereas the 7.0 mmol/L target is within
the range recommended by 2014 Chinese diabetes
guidelines (4.4–7.0 mmol/L) [24] and widely accepted by
Chinese physicians.
Trial status
This study is currently recruiting participants.
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